Patent SG-11201804694S-A (SG)
Title: Dual controls for therapeutic cell activation or elimination
Inventor: BAYLE JOSEPH
IPC: A61K48/00
Filed: 2016-12-13
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau irasYl id (43) International Publication Date .... ......) 22 June 2017(22.06.2017) WIPO I PCT (10) WO International 1111111111113111111111111111111111111111111111111111111111111111111111111111111111111111 2017/106185 Publication A3 Number (51) International Patent Classification: (74) Agents: SILVERSTEIN, C07K 14/705 (2006.01) Cl 2N 5/0783 (2010.01) do CPA Global, A61K 48/00 (2006.01) CO7K 14/47 (2006.01) neapolis, MN 55402 (21) International Application Number: (81) Designated States PCT/US2016/066371 kind of national protection AO, AT, AU, AZ, (22) International Filing Date: BZ, CA, CH, CL, 13 December 2016 (13.12.2016) DO, DZ, EC, EE, (25) Filing Language: English HN, HR, HU, ID, KP, KR, KW, KZ, (26) Publication Language: English MD, ME, MG, MK, (30) Priority Data: NI, NO, NZ, OM, 62/267,277 14 December 2015 (14.12.2015) US RU, RW, SA, SC, TH, TJ, TM, TN, (71) Applicant: BELLICUM PHARMACEUTICALS, INC. ZA, ZM, ZW. [US/US]; 2130 West Holcombe Blvd., Ste. 850, Houston, TX 77030 (US). (84) Designated States kind of regional protection (72) Inventors: BAYLE, Joseph, Henri; 4116 Ruskin St., GM, KE, LR, LS, Houston, TX 77005 (US). DUONG, MyLinh, Thi; 2034 TZ, UG, ZM, ZW), Cypress Bend Lane, Sugarland, TX 77478 (US). TJ, TM), European COLLINSON-PAULZ, Matthew, Robert; 2828 Green- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 900 BA, CN, EG, IL, PA, SD, TR, (US). (unless LA, (unless MW, Eurasian (AL, Sheryl R. et al.; Grant IP, Inc., Second Ave South, Suite 600, Min- otherwise indicated, for every available): AE, AG, AL, AM, BB, BG, BH, BN, BR, BW, BY, CO, CR, CU, CZ, DE, DJ, DK, DM, ES, FI, GB, GD, GE, GH, GM, GT, IN, IR, IS, JP, KE, KG, KH, KN, LC, LK, LR, LS, LU, LY, MA, MN, MW, MX, MY, MZ, NA, NG, PE, PG, PH, PL, PT, QA, RO, RS, SE, SG, SK, SL, SM, ST, SV, SY, TT, TZ, UA, UG, US, UZ, VC, VN, otherwise indicated, for every available): ARIPO (BW, GH, MZ, NA, RW, SD, SL, ST, SZ, (AM, AZ, BY, KG, KZ, RU, AT, BE, BG, CH, CY, CZ, DE, briar Street, Apt 2202, Houston, TX 77098 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, FOSTER, Aaron, Edward; 2244 Swift Blvd, Houston, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, TX 77030 SPENCER, David, Michael; 2811 GW, KM, ML, MR, (US). NE, SN, TD, TG). Prescott Street, Houston, TX 77025 (US). [Continued on next page] (54) Title: DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION xhoi Abbreviation Ncol Nei U3 R US Mean To Annex4 u3 R us EcoR11 - V wahin J GFP iCasp9 GFP+ constructs i eGFP (SD) K k GCCACC (SD) F'F-C- Ser-Giy-Gliy-Gly-Ser 551 13.5 Casp9 9/ %7 CARD f r * (55.8) (13) F'F-C- C-48 1268.5 2.6 r#4 'Pt C88139 c _, S AAA A ,A CARD (591) (a6) F'F 719 a m (60 /4711 7 r Casp9 2) (4.5) F --C- 788.5 26.5 M Casp9 CARD b r (FM) .4t un ( 5,6 ) cc 854 40.2 1-1 0 F-C88p9 . / X ./ 2',- (61,1) (9.4) 1-1 FIG is IN 1-1 (57) : The technology relates in part to methods for controlling the activity or elimination of therapeutic cells using molecu - O lar switches that employ distinct heterodimerizer ligands, in conjunction with other multimeric ligands. The technology may be used, for example to activate or eliminate cells used to promote engraftment, to treat diseases or condition, or to control or modulate the (:) activity of therapeutic cells that express chimeric antigen receptors or recombinant T cell receptors. WO 2017/106185 A3 MIDEDIMOREHMOIDEEEM1111111111 111111E1111 DEN Published: (88) Date of publication of the international search report: — with international search report (Art 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) 27 July 2017